382PDSecond-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma. (23rd October 2018) - Simões, J; Tavares, N T; Borges, C; Meireles, S; Fernandes, C; Costa, A; Caeiro, C; Damasceno, M